Clinical Study
Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis
Table 2
Extracted data on outcomes of interest from all studies.
| | Study/year | Number of patients | Design | Side effects | FVC | DLCO | | | | Prior MMF/MS | During MMF/MS | Prior MMF/MS | During MMF/MS |
| | Liossis et al., 2006 [27] | 6 | RT | 0/6 | 65.6 (19.14) | 76.2 (22.5) | 64.2 (22.55) | 75.4 (26.73) | | Gerbino et al., 2008 [25] | 13 | RT | 2/13 | 70 (15) | 74.3 (14) | 51 (13) | 52.5 (12) | | Zamora et al., 2008 [28] | 17 | RT | 0/17 | 72 (7.8) | 69.4 (11) | 50 (7) | 48.6 (9) | | Koutroumpas et al., 2010 [26] | 10 | RT | 0/10 | 79.5 (15.72) | 87.1 (20.81) | 80.67 (33.52) | 86.67 (25.58) | | Simeon-Aznar et al., 2011 [24] | 14 | PT | 1/14 | 64 (20) | 64 (22) | 40 (13) | 37 (13) | | Tzouvelekis et al., 2012 | 10 | RT | 0/10 | 64.71 (8.7) | 69.44 (10.6) | 51.41 (13.2) | 49.38 (9.2) |
| | Total | 69 | | 3/69 | | | | |
|
|
Data are presented as mean (SD) unless otherwise stated.
Abbreviations: DLCO: diffusing capacity for carbon monoxide, FVC: forced vital capacity, RT: retrospective, PT: prospective, MMF: mycophenolate mofetil, and MS: mycophenolate sodium.
|
